Kojic acid
Star0
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Kojic acid
- DrugBank Accession Number
- DB01759
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 142.1094
Monoisotopic: 142.02660868 - Chemical Formula
- C6H6O4
- Synonyms
- 5-hydroxy-2-(hydroxymethyl)-4-pyrone
- 5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one
- ácido kójico
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism ATyrosinase inhibitorHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image AnubisMed Kojic acid (2.5 g/50mL) + Ammonia (2.75 g/50mL) + Ascorbyl glucoside (0.25 g/50mL) + Ethanol (6.3 mL/50mL) + Ethylhexylglycerin (0.025 g/50mL) + Glycolic acid (17 g/50mL) + Hexylresorcinol (1 g/50mL) + Hydroxyethyl cellulose (0.34875 g/50mL) + Isopropyl alcohol (0.75 g/50mL) + Lactic acid (5 g/50mL) + Phenoxyethanol (0.225 g/50mL) + Propylene glycol (0.5 g/50mL) + Salicylic acid (1 g/50mL) + Water (7.333 mL/50mL) Liquid Topical ANUBIS COSMETICS SL 2022-11-04 2027-07-01 US Cream Kojic acid (3 g/15g) + Glycerin (3.75 g/15g) + Tocopherol (3 g/15g) + Vitamin A (1.5 g/15g) Cream Cutaneous Shantou Youjia E-Commerce Co., Ltd. 2024-02-01 2024-12-31 US Dark Spot Remover Kojic acid (10 mg/100g) + Ascorbic acid (10 mg/100g) + Sodium hyaluronate (10 mg/100g) + Shea butter (20 mg/100g) + Tocopherol (10 mg/100g) + Turmeric (30 mg/100g) + Vitamin A (10 mg/100g) Soap Cutaneous Shantou Youjia E-Commerce Co., Ltd. 2024-02-01 2024-12-31 US Eye Gel Kojic acid (2.25 g/15g) + Hyaluronic acid (3 g/15g) + Nicotinamide (2.25 g/15g) + Vitamin A (4.5 g/15g) Gel Cutaneous Shantou Youjia E-Commerce Co., Ltd. 2024-02-01 2024-12-31 US Instant Face Lift Kojic acid (0.21 mg/30mL) + Marine collagen, soluble (10.5 mg/30mL) + Vitamin A (0.09 mg/30mL) Cream Cutaneous Shantou Youjia E-Commerce Co., Ltd. 2024-02-01 2024-12-31 US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Skin White Pro Strength Kojic and Hyaluronic Skin Lightening Serum Kojic acid (0.3 mg/30mL) + Ascorbic acid (0.3 mg/30mL) + Glycolic acid (0.3 mg/30mL) + Hyaluronic acid (0.3 mg/30mL) + Lactic acid (0.3 mg/30mL) + Nicotinamide (0.3 mg/30mL) + alpha-Arbutin (0.3 mg/30mL) Solution Topical Gazebo Wellness SKIN LLC 2024-10-01 Not applicable US
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as pyranones and derivatives. These are compounds containing a pyran ring which bears a ketone.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Pyrans
- Sub Class
- Pyranones and derivatives
- Direct Parent
- Pyranones and derivatives
- Alternative Parents
- Heteroaromatic compounds / Cyclic ketones / Oxacyclic compounds / Primary alcohols / Organic oxides / Hydrocarbon derivatives / Aromatic alcohols
- Substituents
- Alcohol / Aromatic alcohol / Aromatic heteromonocyclic compound / Cyclic ketone / Heteroaromatic compound / Hydrocarbon derivative / Organic oxide / Organic oxygen compound / Organooxygen compound / Oxacycle
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- primary alcohol, pyranone, enol (CHEBI:43572)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 6K23F1TT52
- CAS number
- 501-30-4
- InChI Key
- BEJNERDRQOWKJM-UHFFFAOYSA-N
- InChI
- InChI=1S/C6H6O4/c7-2-4-1-5(8)6(9)3-10-4/h1,3,7,9H,2H2
- IUPAC Name
- 5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one
- SMILES
- OCC1=CC(=O)C(O)=CO1
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0032923
- KEGG Compound
- C14516
- PubChem Compound
- 3840
- PubChem Substance
- 46506760
- ChemSpider
- 3708
- BindingDB
- 50031467
- 1426451
- ChEBI
- 43572
- ChEMBL
- CHEMBL287556
- ZINC
- ZINC000013831818
- PDBe Ligand
- KOJ
- Wikipedia
- Kojic_acid
- PDB Entries
- 1gqh / 3nq1 / 5i38 / 5m8m / 5m8q
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample dataNot Available Completed Treatment Ocular Hypertension, Primary Open-angle Glaucoma (POAG) 1 somestatus stop reason just information to hide 3 Recruiting Treatment Local Anaesthesia therapy 1 somestatus stop reason just information to hide 2 Completed Treatment Dry Eyes 1 somestatus stop reason just information to hide 2 Not Yet Recruiting Treatment Herpes Simplex Virus Type I Stromal Keratitis 1 somestatus stop reason just information to hide 1 Completed Treatment Healthy Volunteers (HV) 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Liquid Topical Cream Cutaneous Soap Cutaneous Gel Cutaneous Solution Topical - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 153.5 °C PhysProp logP -0.64 KONTOGHIORGHES,GJ (1988) - Predicted Properties
Property Value Source Water Solubility 92.3 mg/mL ALOGPS logP -1 ALOGPS logP -0.5 Chemaxon logS -0.19 ALOGPS pKa (Strongest Acidic) 9.3 Chemaxon pKa (Strongest Basic) -3.1 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 66.76 Å2 Chemaxon Rotatable Bond Count 1 Chemaxon Refractivity 35.27 m3·mol-1 Chemaxon Polarizability 12.63 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9242 Blood Brain Barrier + 0.7522 Caco-2 permeable - 0.5329 P-glycoprotein substrate Non-substrate 0.6369 P-glycoprotein inhibitor I Non-inhibitor 0.8713 P-glycoprotein inhibitor II Non-inhibitor 0.8222 Renal organic cation transporter Non-inhibitor 0.8661 CYP450 2C9 substrate Non-substrate 0.8316 CYP450 2D6 substrate Non-substrate 0.8744 CYP450 3A4 substrate Non-substrate 0.7193 CYP450 1A2 substrate Non-inhibitor 0.9046 CYP450 2C9 inhibitor Non-inhibitor 0.907 CYP450 2D6 inhibitor Non-inhibitor 0.9557 CYP450 2C19 inhibitor Non-inhibitor 0.9025 CYP450 3A4 inhibitor Non-inhibitor 0.909 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.7747 Ames test AMES toxic 0.9016 Carcinogenicity Non-carcinogens 0.9206 Biodegradation Ready biodegradable 0.8904 Rat acute toxicity 2.0673 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9443 hERG inhibition (predictor II) Non-inhibitor 0.9539
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 127.3111855 predictedDarkChem Lite v0.1.0 [M-H]- 127.2862855 predictedDarkChem Lite v0.1.0 [M-H]- 127.2750855 predictedDarkChem Lite v0.1.0 [M-H]- 125.5995 predictedDeepCCS 1.0 (2019) [M+H]+ 128.5054855 predictedDarkChem Lite v0.1.0 [M+H]+ 128.6784855 predictedDarkChem Lite v0.1.0 [M+H]+ 129.1244855 predictedDarkChem Lite v0.1.0 [M+H]+ 128.85225 predictedDeepCCS 1.0 (2019) [M+Na]+ 127.6905855 predictedDarkChem Lite v0.1.0 [M+Na]+ 127.7199855 predictedDarkChem Lite v0.1.0 [M+Na]+ 127.7605855 predictedDarkChem Lite v0.1.0 [M+Na]+ 137.74278 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsTyrosinase
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- This is a copper-containing oxidase that functions in the formation of pigments such as melanins and other polyphenolic compounds. Catalyzes the initial and rate limiting step in the cascade of reactions leading to melanin production from tyrosine (By similarity). In addition to hydroxylating tyrosine to DOPA (3,4-dihydroxyphenylalanine), also catalyzes the oxidation of DOPA to DOPA-quinone, and possibly the oxidation of DHI (5,6-dihydroxyindole) to indole-5,6 quinone (PubMed:28661582)
- Specific Function
- copper ion binding
- Gene Name
- TYR
- Uniprot ID
- P14679
- Uniprot Name
- Tyrosinase
- Molecular Weight
- 60392.69 Da
References
- Zhou Y, Zhang Y, Zhao D, Yu X, Shen X, Zhou Y, Wang S, Qiu Y, Chen Y, Zhu F: TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751. [Article]
Drug created at June 13, 2005 13:24 / Updated at August 26, 2024 19:22